Publications by authors named "M Faham"
Article Synopsis
- AccuScan is a new technology for whole genome sequencing (WGS) of cell-free DNA (cfDNA) that significantly reduces the error rate, making it more reliable for detecting molecular residual disease (MRD).
- It achieves an impressive analytical sensitivity of detecting low levels of cancer variants with 100% specificity in colorectal and esophageal cancers shortly after surgery.
- AccuScan also effectively monitors treatment response in melanoma patients by tracking circulating tumor DNA (ctDNA), demonstrating its utility in predicting disease outcomes without needing large sample amounts.
Article Synopsis
- AccuScan is a new whole genome sequencing (WGS) technology that significantly reduces error rates in analyzing cell-free DNA (cfDNA), achieving a much higher accuracy than previous methods.
- This technology successfully detects molecular residual disease (MRD) with high sensitivity and specificity, particularly in cancers like colorectal and esophageal cancer, and also aids in monitoring responses to immunotherapy in melanoma patients.
- Overall, AccuScan makes it easier and more efficient to detect circulating tumor DNA at very low levels without the need for extensive sample input or complex procedures.
Background: CLA (conjugated linoleic acid)-mediated activation of the schistosome tegument-associated sphingomyelinase and consequent disruption of the outer membrane might allow host antibodies to access the apical membrane antigens. Here, we investigated a novel approach to enhance specific antibody delivery to concealed surface membrane antigens of Schistosoma mansoni utilising antibody-conjugated-CLA nanomicelle technology.
Methodology/principal Findings: We invented and characterised an amphiphilic CLA-loaded whey protein co-polymer (CLA-W) as an IV injectable protein nanocarrier.
Article Synopsis
- Early detection of cancer can significantly reduce morbidity and mortality, and the study explores cell-free DNA (cfDNA) fragmentomics as a promising biomarker for this purpose.
- The research involved analyzing blood samples from 364 cancer patients across six types and 675 healthy individuals, focusing on the cfDNA's genetic features, fragment sizes, and associated protein biomarkers.
- Results indicate that combining ctDNA mutations with protein and fragmentomic data improves cancer detection sensitivity, especially for early-stage cancers, highlighting a potential multifaceted approach to diagnosis.